Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women

References

• 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053
   PubMed Web of Science ®Google Scholar
• Chobanian A V, Bakris G L, Black H R, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252
   PubMed Web of Science ®Google Scholar
• Chobanian A V, Bakris G L, Black H R, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• Lawes C MM, Vander Hoorn S, Law M R, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. I. Estimates of blood pressure levels. J Hypertens 2006; 24: 413–422
   PubMed Web of Science ®Google Scholar
• Lawes C MM, Vander Hoorn S, Law M R, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. II. Estimates of attributable burden. J Hypertens 2006; 24: 423–430
   PubMed Web of Science ®Google Scholar
• Chalmers J, Todd A, Chapman N, et al. International Society of Hypertension (ISH): Statement on blood pressure lowering and stroke prevention. J Hypertens 2003; 21: 651–663
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen T A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206
   PubMed Web of Science ®Google Scholar
• Mosca L, Appel L J, Benjamin E J, et al. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004; 43: 900–921
   PubMed Web of Science ®Google Scholar
• Gierach G L, Johnson B D, Bairey Merz C N, et al. WISE Study Group. Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol 2006; 47(3 Suppl)S50–S58
   PubMed Web of Science ®Google Scholar
• Harrison-Bernard L M, Schulman I H, Raij L. Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. Hypertension 2003; 42: 1157–1163
   PubMed Web of Science ®Google Scholar
• Reckelhoff J F, Fortepiani L A. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004; 43: 918–923
   PubMed Web of Science ®Google Scholar
• Vasan R S, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003–1010
   PubMed Web of Science ®Google Scholar
• Harrison-Bernard L M, Raij L. Postmenopausal hypertension. Curr Hypertens Rep 2000; 2: 202–207
   PubMedGoogle Scholar
• Schulman I H, Aranda P, Raij L, Veronesi M, Aranda F J, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1–7
   PubMedGoogle Scholar
• Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet 2000; 356: 1955–1964
   PubMed Web of Science ®Google Scholar
• Ogden L G, He J, Lydick E, Whelton P K. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539–543
   PubMed Web of Science ®Google Scholar
• Cushman W C, Ford C E, Cutler J A, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393–405
   PubMedGoogle Scholar
• Black H R, Elliott W J, Neaton J D, et al. Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension 2001; 37: 12–18
   PubMed Web of Science ®Google Scholar
• Svetkey L. Management of prehypertension. Hypertension 2005; 45: 1056–1061
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360: 1903–1913
   PubMed Web of Science ®Google Scholar
• Vasan R S, Larson M G, Leip E P, et al. Impact of high-normal blood pressure on cardiovascular disease. N Engl J Med 2001; 345: 1291–1297
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt S D, Egan B M, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697
   PubMed Web of Science ®Google Scholar
• Lewis E J, Hunsicker L G, Bain R P, Rohde R D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945
   PubMed Web of Science ®Google Scholar
• Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet 1997; 349: 1857–1863
   PubMed Web of Science ®Google Scholar
• Brenner B M, Cooper M E, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869
   PubMed Web of Science ®Google Scholar
• Lewis E J, Hunsicker L G, Clarke W R, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Parving H H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme W J, Cody, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321
   PubMed Web of Science ®Google Scholar
• Rocha R, Chander P N, Khanna K, Zuckerman A, Stier C T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451–458
   PubMed Web of Science ®Google Scholar
• Weber K T. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689–1697
   PubMed Web of Science ®Google Scholar
• Farquiharson C AJ, Struthers A D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594–597
   PubMed Web of Science ®Google Scholar
• MacFadyen R J, Barr C S, Struthers A D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30–34
   PubMed Web of Science ®Google Scholar
• Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001; 19: 829–842
   PubMed Web of Science ®Google Scholar
• Grandi A M, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic dysfunction in essential hypertension. Hypertension 2002; 40: 647–652
   PubMed Web of Science ®Google Scholar
• Mück A O, Seeger H. Effect of hormone therapy on blood pressure in normotensive and hypertensive postmenopausal women. Maturitas 2004; 49: 189–203
   PubMed Web of Science ®Google Scholar
• Karalis I, Beevers D G, Beevers M, Lip G YH. Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. Blood Press 2005; 14: 38–44
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997; 27: 261–274
   PubMed Web of Science ®Google Scholar
• Oelkers W. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin–aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–1821
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater E P, Fritzemeier K H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–251
   PubMed Web of Science ®Google Scholar
• Oelkers W. Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Steroids 1996; 61: 166–171
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier K H, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995; 761: 311–335
   PubMed Web of Science ®Google Scholar
• Norman P, Castaner J, Castaner R M. Drospirenone. Drugs Future 2000; 25: 1247–1256
   Web of Science ®Google Scholar
• Archer D F, Thorneycroft I H, Foegh M, et al. Long-term safety of drospirenone–estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–727
   PubMed Web of Science ®Google Scholar
• White W B, Pitt B, Preston R A, Hanes V. Antihypertensive effects of drospirenone with 17-beta-estradiol, a novel hormone treatment in post-menopausal women with stage 1 hypertension. Circulation 2005; 112: 1979–1984
   PubMed Web of Science ®Google Scholar
• White W B, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17β-estradiol, in post-menopausal women with hypertension. Hypertension 2006; 48: 246–253
   PubMed Web of Science ®Google Scholar
• Preston R A, Alonso A, Panzitta D, Zhang P, Karara A H. Additive effect of drospirenone/17-beta estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002; 15: 816–822
   PubMed Web of Science ®Google Scholar
• Preston R A, White W B, Pitt B, Bakris G, Norris P M, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797–804
   PubMed Web of Science ®Google Scholar
• Preston R A, Norris P M, Alonso A B, Ni P, Hanes V, Karara A H. Randomized, placebo-controlled, trial of the effects of drospirenone–estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007, in press
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix S L, Limacher M, , for the WHI Investigators, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 2003; 289: 2673–2684
   PubMed Web of Science ®Google Scholar
• Steiner A Z, Hodis H N, Lobo R A, Shoupe D, Xiang M, Mack W J. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: The Estrogen in the Prevention of Atherosclerosis Trial. Menopause 2005; 12: 728–733
   PubMed Web of Science ®Google Scholar